CytoDyn closes $16.5 million financing to fund leronlimab development
CytoDyn says it has closed a $16.5 million financing to fund continued development of leronlimab, its humanized monoclonal antibody targeting the CCR5 receptor.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.